Russell Investments Group’s Telix Pharmaceuticals TLX Stock Holding History

Russell Investments Group’s Portfolio TLX Stock Details TLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-60,301	Closed	-$975K	–	4244
2025 Q2	$975K	Buy	+60,301	New	+$1.01M	﹤0.01%	2076

Other funds holding TLX

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

PIC

Portland Investment Counsel Burlington, Ontario, Canada $312M AUM 53.32% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

PAG

Private Advisor Group Morristown, New Jersey $21.3B AUM 22.13% 1-Year Est. Return

IWM

IHT Wealth Management Chicago, Illinois $4.3B AUM 21.02% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPIM

Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return

Russell Investments Group's TLX Position: Q3 2025 in Review

Russell Investments Group sold out of Telix Pharmaceuticals (TLX) in Q3 2025, closing a stake of 60,301 shares — an estimated $975K sold.

Russell Investments Group first reported a position in TLX in Q2 2025 and held it in 1 quarter. The position peaked at $975K in Q2 2025. 27 funds tracked by Wall St. Rank hold TLX as of Q3 2025.

Russell Investments Group reported no remaining Telix Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
Russell Investments Group sold 60,301 Telix Pharmaceuticals shares in Q3 2025, an estimated $975K.
Russell Investments Group first reported a position in Telix Pharmaceuticals in Q2 2025 and held it in 1 quarter.
Russell Investments Group's Telix Pharmaceuticals position peaked at $975K in Q2 2025.
27 funds tracked by Wall St. Rank held Telix Pharmaceuticals as of Q3 2025.

Based on Russell Investments Group's 13F filing for Q3 2025, filed 13 Nov 2025.